Fermer le menu


Member of Lyonbiopole


VetoPhage is a Biotech company specialized in bacteriophage research and development. Phage-based therapy is an innovating approach to treating a wide variety of bacterial infections, in particular drug-resistant strains of bacteria.  The research work is supervised by Prof. Yves Waché and Dr. Mai Huong Ly-Chatain who have more than 10 years experience on phages.The objective of VetoPhage is to develop the « proof of concept » for the diagnostic and treatment of pathogenic bacteria in livestock and in aquaculture. Bacterial resistance to antibiotics is increasing dramatically both in animal health and in human health. So thanks to a “one health” concept, we need to provide new solutions to fight against this increasing fear. The objective of VetoPhage is to finalize the « proof of concept » and develop innovating tools for the diagnostic and treatment of pathogenic bacteria in livestock and in aquaculture. Bacteriophage solutions are safe, environmentally friendly, natural and effective, we continue to isolate phages and develop phage applications.We dedicate subcontract your R&D projects or answer to your specific needs. The revenue derives from the sale of new products in specific markets or from the deal for licensing agreements with our partners. 

Vetophage's first bovine mastitis products will be available for the market in 2023. It is a new type of rapid detection tools for pathogenic bacteria responsible for bovine mastitis.


Strategic application domain: Veterinary Medicine

Application market: Infectious Diseases, Veterinary medicine

Type of activity: Diagnostics, Therapeutics, Pharma or Biotech

Technologies: Others

Created on feb. 6th, 2017 - 9 employees



2 Allée du Lazio 69800 Saint Priest



Vous devez être connecté et membre de Lyonbiopôle pour voir les contacts.

R&D projects